Amimo Floriano, Lambert Ben, Magit Anthony, Hashizume Masahiro
Department of Global Health Policy, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan.
Faculty of Medicine, Eduardo Mondlane University, Maputo, Mozambique.
Global Health. 2021 Apr 8;17(1):42. doi: 10.1186/s12992-021-00666-8.
The ongoing pandemic of coronavirus disease 2019 (COVID-19) has the potential to reverse progress towards global targets. This study examines the risks that the COVID-19 pandemic poses to equitable access to essential medicines and vaccines (EMV) for universal health coverage in Africa.
We searched medical databases and grey literature up to 2 October 2020 for studies reporting data on prospective pathways and innovative strategies relevant for the assessment and management of the emerging risks in accessibility, safety, quality, and affordability of EMV in the context of the COVID-19 pandemic. We used the resulting pool of evidence to support our analysis and to draw policy recommendations to mitigate the emerging risks and improve preparedness for future crises.
Of the 310 records screened, 134 were included in the analysis. We found that the disruption of the international system affects more immediately the capability of low- and middle-income countries to acquire the basket of EMV. The COVID-19 pandemic may facilitate dishonesty and fraud, increasing the propensity of patients to take substandard and falsified drugs. Strategic regional cooperation in the form of joint tenders and contract awarding, joint price negotiation and supplier selection, as well as joint market research, monitoring, and evaluation could improve the supply, affordability, quality, and safety of EMV. Sustainable health financing along with international technology transfer and substantial investment in research and development are needed to minimize the vulnerability of African countries arising from their dependence on imported EMV. To ensure equitable access, community-based strategies such as mobile clinics as well as fees exemptions for vulnerable and under-served segments of society might need to be considered. Strategies such as task delegation and telephone triage could help reduce physician workload. This coupled with payments of risk allowance to frontline healthcare workers and health-literate healthcare organization might improve the appropriate use of EMV.
Innovative and sustainable strategies informed by comparative risk assessment are increasingly needed to ensure that local economic, social, demographic, and epidemiological risks and potentials are accounted for in the national COVID-19 responses.
2019年冠状病毒病(COVID-19)的持续大流行有可能扭转在实现全球目标方面取得的进展。本研究探讨了COVID-19大流行给非洲实现全民健康覆盖的基本药物和疫苗(EMV)公平可及性带来的风险。
我们检索了截至2020年10月2日的医学数据库和灰色文献,以查找报告有关前瞻性途径和创新战略数据的研究,这些数据与在COVID-19大流行背景下评估和管理EMV在可及性、安全性、质量和可负担性方面的新出现风险相关。我们利用所得的证据库来支持我们的分析,并得出政策建议,以减轻新出现的风险并提高对未来危机的防范能力。
在筛选的310条记录中,134条被纳入分析。我们发现,国际体系的中断对低收入和中等收入国家获取EMV篮子的能力产生了更直接的影响。COVID-19大流行可能助长欺诈行为,增加患者服用不合格和假冒药品的倾向。以联合招标和合同授予、联合价格谈判和供应商选择以及联合市场研究、监测和评估等形式的战略区域合作,可以改善EMV的供应、可负担性、质量和安全性。需要可持续的卫生筹资以及国际技术转让和大量研发投资,以尽量减少非洲国家因依赖进口EMV而产生的脆弱性。为确保公平可及,可能需要考虑基于社区的战略,如移动诊所,以及为社会弱势群体和服务不足群体免除费用。任务委托和电话分诊等战略有助于减轻医生的工作量。这再加上向前线医护人员和具备健康素养的医疗机构支付风险津贴,可能会改善EMV的合理使用。
越来越需要基于比较风险评估的创新和可持续战略来确保在各国应对COVID-19的措施中考虑到当地的经济、社会、人口和流行病学风险及潜力。